Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension

The study will compare the safety and efficacy of Bimatoprost and Latanoprost in patients with glaucoma or ocular hypertension

Intervention(s) in this Clinical Trial

• Drug: bimatoprost 0.03% eye drops
  • Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of bimatoprost 0.03% 1 drop every evening for 12 weeks
• Drug: latanoprost 0.005% eye drops
  • Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of latanoprost 0.005% 1 drop every evening for 12 weeks

Arms, Groups and Cohorts in this Clinical Trial

• Active Comparator: 1
  • bimatoprost 0.03% eye drops
• Active Comparator: 2
  • latanoprost 0.005% eye drops

Primary Measures

• Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Week 12
  • Time Frame: Baseline, Week 12
    Safety Issue?: No
• Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Week 18
  • Time Frame: Baseline, Week 18
    Safety Issue?: No

Inclusion Criteria:

• Ocular hypertension or chronic glaucoma
• Patient requires IOP-lowering therapy in both eyes

Exclusion Criteria:

• Uncontrolled medical conditions
• Hypersensitivity to study medications

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: Allergan Industry

Overall Clinical Trial Officials and Contacts

Medical Director Study Director Allergan  

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00541242

Study ID Number: 192024-034

ClinicalTrials.gov Identifier: NCT00541242

Health Authority: United States: Institutional Review Board